Trial Profile

CARE II - Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-Country, Multi-Centre Phase IV Study

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Quetiapine (Primary)
Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
Focus Therapeutic Use
Acronyms CARE-II
Sponsors AstraZeneca

Most Recent Events

30 Oct 2008 Planned number of patients was 200, the actual number enrolled was 7, according to ClinicalTrials.gov record.
30 Oct 2008 Status changed from not yet recruiting to discontinued according to ClinicalTrials.gov record.
10 Jun 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com